55 results on '"Provencio Pulla, M."'
Search Results
2. P2.31-12 Sexual Dysfunction on Patients with Lung Cancer: Results from the CLARIFY Project
3. EP17.01-02 Data Mining to Build Metrics. A Feasible Assessment of Quality of Care for Stage III Non-small Cell Lung Cancer (NSCLC)
4. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816
5. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
6. 490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
7. P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
8. 1064P Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis
9. 1604P Assessing lung cancer patients' unplanned hospitalizations, a cohort study to find care gaps: Tracking what is trackable
10. 1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)
11. 42P Real-life data on treatment with poly (ADP-ribose) polymerase inhibitor (iPARP), in patients over 65 years of age with ovarian cancer: A current need
12. 220P Distant disease-free survival according to different subtypes in young breast cancer patients (YBCP)
13. 39P Determination of essential biomarkers in lung cancer: A real-world data study in Spain
14. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
15. 53P Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)
16. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
17. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
18. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
19. 829MO A gene signature to predict risk of transformation in patients with follicular lymphoma
20. 749P Cardiotoxicity in patients treated with PARP-inhibitors
21. 143P Fertility rates in young breast cancer patients (YBCP) and evolution: A new challenge
22. 175P Tumour biology in young breast cancer patients (YBCP): A different disease?
23. 133P Breast cancer in young women (BCYW): Different entity or different needs?
24. 149P Restricted mean survival time (RMST): A new tool for time to event analysis in young breast cancer patients (YBCP)
25. 174P Breast screening at young age: A real need?
26. 39P Analysis of bloodstream infections in oncological patients
27. 1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
28. 245P Breast cancer in young women (BCYW): Clinical impact of diagnosis in asymptomatic patients
29. 889MO Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group
30. 1786P Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)
31. 1883P Fertility rates in Spanish young breast cancer patients (YBCP)
32. 244P Breast cancer in young women (BCYW): Real world data to fill the gap and find the needs
33. 1733P Real-world data: Cancer and SARS-CoV-2 infection
34. Prospective study of circulating tumor cells in long survivors of immunotherapy
35. RING observational trial to compare T790M mutation testing in blood by different methodologies
36. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
37. GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC
38. Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
39. Palliative care in advanced cancer: A clinical and ethical goal achieved?
40. Event free survival at 24 months: A new endpoint in diffuse large B-cell lymphoma
41. Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study” NADIM trial
42. Preliminar analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): NORA trial (GECP 15/02)
43. Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma
44. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
45. Staging and assessment of the response to PET-CT treatment in non-small cell lung carcinoma
46. Follicular lymphoma: clinical and mollecular characteristics of histologic transformation
47. Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC
48. Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
49. Snps in Angiogenic Factors As Predictive Markers for Outcome in Patients (P) with Advanced Non-Squamous Nsclc (NS-NSCLC) Treated with Carboplatin, Paclitaxel (CP) and Bevacizumab (BEV). Final Results of Angiomet Spanish Lung Cancer Group Trial
50. Thoracic Malignancies and Other Second Neoplasms in Hodgkin Lymphoma Survivors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.